CD19-AND CD22-BASED COMBINED CAR-T IMMUNOTHERAPY

摘要

Provided is an immune cell mixture comprising an immune cell genetically modified with a chimeric antigen receptor targeting CD19 and an immune cell genetically modified with a chimeric antigen receptor targeting CD22. The chimeric antigen receptor targeting CD19 and the chimeric antigen receptor targeting CD22 each comprises an antigen-binding domain, a transmembrane domain, a costimulatory signaling region, a CD3ζ signaling domain, and an inducible suicide fusion domain in tandem arrangement. The chimeric antigen receptors specifically recognize tumor surface antigens CD19 and CD22. Compared to using other single-targeted chimeric antigen receptor T cells, using CAR-T cells targeting two antigens achieves better therapeutic effects, which makes CD19 escape not easy to occur, and allows the disease to be easily relieved.